This article is part of the HBOT Radar series, where we summarize the latest published hyperbaric oxygen therapy research.
Disclaimer: This article is intended for educational and informational purposes only. It summarizes published medical research conducted in clinical settings and does not evaluate Brain Spa Hyperbaric products. The hyperbaric chambers offered on this website are non-medical wellness devices and are not intended to diagnose, treat, cure, or prevent any disease. Do not make medical decisions based on this article — consult a qualified healthcare professional.
Title:
New review shows how hyperbaric oxygen could strengthen chemotherapy, radiotherapy and immunotherapy
What this review is about
Cancer tumours often grow in low-oxygen environments, a problem called hypoxia.
Hypoxia is one of the biggest reasons why cancer treatments fail or become less effective.
This new scientific review looked at how hyperbaric oxygen therapy may help overcome this oxygen shortage and make many cancer treatments work better.
The paper connected findings from biology, preclinical studies and early clinical trials, setting out how hyperbaric oxygen might influence multiple treatment pathways at once.
What kind of paper this is. This is a narrative review, not a trial or a meta-analysis. Its authors gathered laboratory work, animal studies and early clinical findings and assembled them into an argument. That makes it useful for understanding why researchers think hyperbaric oxygen might matter in oncology — and unsuitable for concluding that it does.
Key insights from the review
1. The oxygen problem, and what the authors propose
Hyperbaric oxygen increases dissolved oxygen in the blood far more than normal breathing can.
This reaches deep into tumour tissue and helps:
- reduce hypoxia
- make cancer cells less resistant
- improve therapeutic response
2. The chemotherapy argument
Oxygenated tumour tissue allows chemotherapy drugs to penetrate deeper and work better.
Hypoxic cancer cells often resist chemotherapy. The authors argue that raising tissue oxygen should reduce that resistance — a proposal grounded in cell biology rather than in trial results.
3. The radiotherapy argument
Radiation biology has established for decades that oxygen amplifies radiation-induced DNA damage. Whether hyperbaric oxygen delivers enough of it, at the right moment, to change outcomes is the part still being worked out.
4. The immunotherapy argument
Hypoxia suppresses the immune system around the tumour.
The authors propose that re-oxygenating the area could improve immune activation and support treatments such as checkpoint inhibitors. This part of the review is largely preclinical.
5. HBOT affects important biological pathways
The review highlights several mechanisms influenced by HBOT:
- oxidative stress regulation
- ferroptosis (a form of cell death relevant to killing cancer cells)
- angiogenesis (blood vessel formation)
- cancer stem cell behaviour
- tumour microenvironment remodeling
These pathways are involved in treatment resistance, and the review sets out how hyperbaric oxygen might influence each of them. "Might" is doing real work in that sentence — this is a mechanistic map, not an outcome study.
Important nuance: the paper also discusses challenges
The authors emphasise that we still need:
- clearer dose-response studies
- better understanding of long-term safety in specific cancers
- insight into when HBOT’s pro-angiogenic effects might be helpful or not
- precision tools to identify which patients benefit most
One of those caveats deserves more than a bullet point. Hyperbaric oxygen promotes angiogenesis — the growth of new blood vessels. In wound healing that is the whole point. In a tumour, new blood vessels are not obviously desirable. The review flags this as unresolved, and it is the reason hyperbaric oxygen in cancer is studied under oncologist supervision rather than adopted on the strength of the mechanism.
Why this matters
Cancer hypoxia is one of the hardest problems in oncology.
Any therapy that reduces hypoxia can potentially:
- increase treatment success
- reduce resistance
- improve patient outcomes
What makes the idea attractive is that hyperbaric oxygen is non-invasive and touches several of these mechanisms at once rather than one.
The authors suggest that integrating HBOT into multi-modal cancer treatment could become an important strategy in personalised medicine.
Takeaway for THE community
This 2025 review sets out the case for hyperbaric oxygen as a supportive element in oncology — not replacing standard therapy, but potentially making it work better by addressing tumour hypoxia. It is a case being made, not a conclusion being reported.
The mechanisms the review proposes are that oxygen could help:
- chemotherapy reach deeper into tumours
- radiotherapy damage cancer cells more effectively
- immunotherapy activate the immune system more strongly
- reduce cancer’s ability to resist treatment
HBOT Radar will continue tracking the latest evidence on how hyperbaric oxygen fits into future cancer therapy.
Study link: https://pubmed.ncbi.nlm.nih.gov/41172962/
Educational disclaimer
This content summarizes findings from published medical research for educational purposes only.
The hyperbaric chambers sold on this website are non-medical wellness devices and are not intended to diagnose, treat, cure, or prevent any disease.
The studies discussed here were conducted in clinical medical settings using medical-grade interventions. The inclusion of research summaries does not imply that similar outcomes can be achieved using non-medical wellness devices.
